Neurocrine announces FDA approval of crenessity

Neurocrine (NBIX) Biosciences announced the U.S. FDA has approved crenessity capsules and oral solution as an adjunctive treatment to glucocorticoid replacement to control androgens in adult and pediatric patients four years of age and older with classic congenital adrenal hyperplasia, a rare, serious and lifelong genetic condition involving the adrenal glands. Crenessity a potent and selective oral corticotropin-releasing factor type 1 receptor antagonist, is the first and only classic CAH treatment that directly reduces excess adrenocorticotropic hormone and downstream adrenal androgen production, allowing for glucocorticoid dose reduction. It is a breakthrough in the treatment landscape for classic CAH.